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Vaccines, analgesia and antibiotics embody some of the most enduring
therapeutic breakthroughs that have transformed medicine. Building on such
fine paradigms of biomedical innovation, the evolution of technologies has
increasingly sparked spectacular advances across the continuum of wellness
and disease spanning medical and surgical specialties. Discovery science fueled by government and private sector resources - has systematically
instituted the principles of modern healthcare delivery ensuring that medical
practice is based on up-to-date scientific evidence. The harmony between
science, technology, and resources has culminated in a golden age of
discovery and translation, eradicating infections, curing cancers, and palliating
endocrine and metabolic diseases. Indeed, proven therapeutic and preventive
approaches have progressively moved into everyday practice.
The success of the science-medicine union has spurred public and private
sector investments, further fueling the engine of discovery and enabling
technology. This integration produced the new biology, enabling advances in
technology

platforms

to

offer

unprecedented

opportunities

in

disease

prediction, prevention, and even cure beyond the reach of traditional
healthcare solutions. Modern science offers outstanding opportunities to probe
the innermost workings of the human body, and to understand how events at
the subcellular and molecular levels influence the functioning and integrity of
the individual

as a whole.1,2 Remarkable progress is being made in

understanding the molecular, genetic, and cellular origins of disease, and
opportunities now exist to uncover practical uses for this new knowledge,
particularly in the realm of personalized medicine.3,4
Unexpectedly, however, acceleration in enabling technologies and the
resultant insights into basic pathophysiological mechanisms has outstripped the
capacity of current scientific and clinical structures to efficiently manage their
3

translation into new paradigms to improve the health and quality of life of
individuals, communities and populations.5 In that context, federally-funded
research programs have produced hundreds, if not thousands, of new diseaserelated molecular targets that represent potential diagnostic and therapeutic
targets for tailored disease management.6 Unfortunately, their applications
remain only a distant promise, reflecting a limited capacity in structures,
resources and the specialized workforces required for their translations into new
healthcare paradigms. Compounding these challenges is the reality that 95% of
promising therapies brought into clinical development in the private sector
ultimately fail because of limitations in efficacy or unacceptable toxicities.
Further research is needed to identify, measure, and validate targets and
pathways that have been detected in basic studies, and then to develop new
clinical applications and rigorously evaluate their effectiveness and safety.
Indeed, further understanding of the translation process itself must occur to
expedite and expand the adoption of biomedical advances into clinical
practice and individual health behaviors.
Recognition of the need to rebalance the equation, and bring translation
into register with the power, progress, and pace of discovery science and
associated enabling technologies is reflected in the recent enactment of the
Cures Acceleration Network (CAN), legislation that seeks to bridge the chasm
between basic scientific discoveries and new health treatments.7 Part of the
Patient Protection and Affordable Care Act, CAN mandates that the National
Institutes of Health (NIH) advance the development of highly needed cures by
reducing barriers between research discovery and translation. The CAN
provisions grant NIH flexibility to carry out therapeutic development projects and
underscore the expectations of Congress and the American public that the NIH
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will have a catalytic role in moving scientific discovery along the continuum that
ultimately creates advances in human health.
The leadership of the NIH, embracing this mandate to accelerate
translation inherent in CAN, charged its Scientific Management Review Board
with defining a path forward to rebalance the equation. Those deliberations
resulted in the near-unanimous suggestion by the SMRB to constitute a new
National Center for Advancing Translational Sciences. The charge of this new
Center will include:
•

Advancing novel molecular discoveries across the translational Valley
of Death into promising technologies with a more favorable riskbenefit ratio that will appeal to the private sector for further
development into novel modalities that change patient care.8

•

Consolidating the considerable resources already existing in NIH
programs and cores that can facilitate the development of molecular
science across the translational continuum.

These will include the

Molecular Libraries Program (MLP) which offers access to high
throughput screening capabilities and libraries of compounds useful
for research and as therapeutics. For example, the Chemical
Genomics Center, part of MLP, provides a robotic, high throughput
screening system and a library of >350,000 small molecules to
interrogate fundamental cellular mechanisms. The Therapeutics for
Rare and Neglected Diseases program provides resources for
preclinical drug development centered on rare disorders with limited
commercial interest. Finally, Clinical and Translational Science Awards
offer a linked nationwide network of institutions providing the
infrastructure and workforce to advance the development of
therapeutic through patient and community-based studies.9
5

•

Nucleating interactions between public and private sectors that
maximize the utility of technology resources, distribute risk to lower
barriers

to

orchestrate

commercialize
the

appropriate

academic-government,
along

the

diagnostics

and

organizational

therapeutics,

and

transitions

(e.g.,

government-pharmaceutical

developmental

continuum

to

optimize

company)
translational

efficiencies.
•

Leading the development of the next generation of clinical and
translational investigators. Rebalancing the equation to equilibrate
discovery and translational science will necessitate developing a
cadre of investigators fluent in the lexicons of the laboratory and
clinic.10 They must understand the widely different paradigms
underlying laboratory-based experimentation and clinical diagnosis
and therapy, enabling integration of these structures in which critical
unmet gaps in patient care drive the evolution of science. Moreover,
they will require a transformation in professional culture that incents
science practiced as part of multidisciplinary teams, rather than the
current silos which reward individual contributions.11,12

The creation of the National Center for Advancing Translational Sciences
evidences a broad contemporary vision of the investigational continuum from
molecules, to patients and populations. It anticipates the evolution of translation
from a science focused on new therapeutic modalities for disease palliation, to
the assessment of risk and the science of wellness and disease prevention.13,14
The Center will leverage existing and emerging resources to maximize
productivity in the form of better health and quality of life. Moreover, it brings
divergent stakeholders to the table, across traditionally insular communities of
practice, and invests them in a public-private partnership and an envisioned
6

future in which science is the engine driving translation and clinical
development to amplify efficiencies and reduce risks associated with improving
patient care.
While this bold step marks a sea change in the way the science of
translation is conducted in the United States, the leaders of the NIH continue
their forward-looking vision, anticipating challenges that could attenuate the
impact of the new center. Those considerations include:
•

The science of translation will maximally benefit from the broadest
participation of the widest communities of practice. Teams of clinical
and translational investigators will cut across disciplines, guilds, and
cultures where individual knowledge and skill sets are valued for their
potentiation of the greater goals. Teams will include physicians,
scientists, engineers, pharmacists, therapists and others contributing to
the generation of new insights, their operationalization into new
modalities of healthcare, and their dissemination across populations,
communities, and the global landscape. Conversely, the science of
translation cannot be the purview of any specific clinical and scientific
discipline. Indeed, restricting the science of translation to ownership by
a single discipline jeopardizes the success of the entire enterprise.

•

The science of drug development traditionally has been the focus of
the biopharmaceutical industry, which has been the primary source of
new diagnostic and therapeutic modalities for managing patients.15,16
Even in the face of their considerable innovation and expertise, the
success rate for new drugs is less then 5%, and success is associated
with a price tag topping $1 billion. One goal of the new center will to
accelerate the translation of the hundreds of new targets into
promising therapeutic compounds in early clinical trials. The goal is to
7

“de-risk” these targets and agents, to make them more attractive to
biopharmaceutical partners, who will advance them into late stage
trials in anticipation of regulatory approval and marketing. One central
consideration in this model is how the new center and its partners will
“beat the odds” inherent in drug development. Indeed, while the
pharmaceutical industry has the deepest expertise in this field, invests
as much, if not more, capital resources into research as does the NIH,
and is powerfully motivated by profit and investor satisfaction for
success, the success rate remains very low. The architects of the new
center are considering novel models, paradigms, and collaborations
that increase the success rate required to accommodate enhanced
throughput represented by translation of the backlog of new markers
and targets.
•

A correlative consideration is the measurement of success in this new
endeavor, a core consideration for the new center. While the goals for
enhancing translational science are clear, the methods to measure
enhancement are less straightforward. Logically, the gold standard
would be the number of new therapeutic agents being translated into
patient care algorithms. However, this is particularly complicated by
the very long timelines inherent in the drug development process.
Indeed, it can take up to 15-20 years for a new entity to move from
discovery into late stage clinical trials and regulatory submission. More
proximal surrogate metrics, for example numbers of new therapeutics
advanced into clinical trials, suggest activity in the system but do not
address whether this activity is optimally productive, or is even
commensurate with the track record of the pharmaceutical industry,
acknowledged leaders in this field. Thus, it will not be sufficient to show
8

metrics of utility or traditional markers of interim performance. Rather,
the challenge will be to identify markers of performance that correlate
closely with ultimate success. This is not a trivial task and the
biopharmaceutical industry has been chasing this ideal, without
apparent success.
•

New center activities are decidedly focused on the earliest stages of
the translational continuum. Indeed, the focus for this organization is on
discovery, target validation, preclinical animal models, and early stage
clinical trials, including T1 translation in which safety and tolerability are
established, and T2 translation, in which efficacy is first explored.1,17
However, equally important are T3 and T4 translation. In T3 translation,
new knowledge surrounding the clinical application of discoveries
revealed in T1 and T2 must be disseminated into community
practices.1,17 This critical step, and the associated gap and essential
unmet clinical need, was only revealed once it was recognized that
breakthrough discoveries failed to optimally translate into community
practice. This gap in dissemination represents one primary limitation
restricting the application of new discoveries to global populations.
While T1 and T2 translation involve well-established skill sets and
processes, T3 challenges the enterprise to innovate concepts and
methods to disseminate new clinical knowledge for integration into
practice,

including

health

services

research,

community-based

participatory research, and comparative effectiveness research.
Beyond

incorporating

evidence-based

knowledge

into

clinical

practice, T4 translation seeks to advance scientific knowledge beyond
algorithms of palliation treating established disease, to paradigms of
disease prevention through lifestyle and behavioral alterations in
9

communities and populations. It is at this stage of translation that the
enterprise undergoes a strategic evolution from a medical model of
clinical practice (intervention), to a public health model of disease
management (prevention). Here, the public health model focuses on
information and education programs that eliminate deleterious
behaviors at the community and population levels that produce
disease susceptibility.18 In essence, T4 research seeks to move health
practices established in T3 into population health impact, associated
with improved disease prevention and reduced costs for medical care.
Skill sets central to T4 translation include the well-established paradigms
for public health and population research and emerging areas
including outcomes research. Together, these considerations highlight
the essential nature of the entire T1-T4 translational continuum to
accelerate discovery into new paradigms for the management of
patients and communities.
Formation of the new National Center for Advancing Translational
Sciences represents a critical exponential step in the evolution of the science of
translation.19,20 It amalgamates national resources and programs whose
centralization and integration will facilitate discovery and early development. It
will nucleate public-private partnerships that hold the promise of accelerating
new insights in molecular mechanisms underlying pathophysiology into novel
diagnostics and therapeutics. Moreover, it will create a career path in clinical
and translational science and medicine that will prepare the next generation of
skilled investigators invested the culture of team science. This great promise and
potential can only be realized in the context of solving the great challenges that
work to minimize the impact of translation on the healthcare of populations:
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inclusion of broad communities of practice, failure rates in drug development,
metrics of performance, and covering the translational medicine continuum.
The new National Center can be viewed as one bold example of visionary
disruptive innovation, in which traditional structures are reconfigured in
unanticipated ways to achieve exponential evolution in a field. In that context,
the new Center provides an unprecedented opportunity to recast science and
medicine in response to the evolving needs of our patients while sustaining
affordable healthcare. Here, translational medicine represents the critical next
evolutionary step in realizing the clinical value of the new biology in order to
drive discovery into personalized health care solutions. By offering paradigms to
predict, prevent, treat and cure disease, translational medicine will be poised to
enable application of transformative diagnostics, prognostics and therapies that
promote longitudinal wellness and advance health care for individuals and
populations. The ultimate mandate for the new National Center is to secure
early adoption of the integration of discovery innovation into clinical practice in
response to patients and society who seek new products and services to
address unmet needs.
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